 Serotonin 5-HT3 Receptor Antagonists
"Serotonin 5-HT3 Receptor Antagonists" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Drugs that bind to but do not activate SEROTONIN 5-HT3 RECEPTORS, thereby blocking the actions of SEROTONIN or SEROTONIN 5-HT3 RECEPTOR AGONISTS.
| Descriptor ID |
D058831
|
| MeSH Number(s) |
D27.505.519.625.850.850.300 D27.505.696.577.850.850.300
|
| Concept/Terms |
Serotonin 5-HT3 Receptor Antagonists- Serotonin 5-HT3 Receptor Antagonists
- Serotonin 5 HT3 Receptor Antagonists
- 5-HT3 Antagonist
- 5 HT3 Antagonist
- Antagonist, 5-HT3
- 5-HT3 Antagonists
- 5 HT3 Antagonists
- Antagonists, 5-HT3
|
Below are MeSH descriptors whose meaning is more general than "Serotonin 5-HT3 Receptor Antagonists".
Below are MeSH descriptors whose meaning is more specific than "Serotonin 5-HT3 Receptor Antagonists".
This graph shows the total number of publications written about "Serotonin 5-HT3 Receptor Antagonists" by people in this website by year, and whether "Serotonin 5-HT3 Receptor Antagonists" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2003 | 0 | 1 | 1 | | 2004 | 0 | 2 | 2 | | 2006 | 1 | 2 | 3 | | 2007 | 2 | 1 | 3 | | 2009 | 1 | 0 | 1 | | 2013 | 0 | 1 | 1 | | 2014 | 1 | 0 | 1 | | 2015 | 1 | 0 | 1 | | 2016 | 1 | 1 | 2 | | 2017 | 0 | 1 | 1 | | 2018 | 1 | 0 | 1 | | 2019 | 1 | 1 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Serotonin 5-HT3 Receptor Antagonists" by people in Profiles.
-
Chow R, Aapro M, Navari RM, Gralla R, Chiu N, Chiu L, Chan S, Popovic M, Lam H, Lock M, DeAngelis C. Do we still need to study palonosetron for chemotherapy-induced nausea and vomiting? A cumulative meta-analysis. Crit Rev Oncol Hematol. 2019 Oct; 142:164-186.
-
Basak S, Gicheru Y, Kapoor A, Mayer ML, Filizola M, Chakrapani S. Molecular mechanism of setron-mediated inhibition of full-length 5-HT3A receptor. Nat Commun. 2019 07 19; 10(1):3225.
-
Chow R, Warr DG, Navari RM, Tsao M, Popovic M, Chiu L, Milakovic M, Lam H, DeAngelis C. Should palonosetron be a preferred 5-HT3 receptor antagonist for chemotherapy-induced nausea and vomiting? An updated systematic review and meta-analysis. Support Care Cancer. 2018 Aug; 26(8):2519-2549.
-
Navari RM. Management of Chemotherapy-Induced Nausea and Vomiting in Pediatric Patients. Paediatr Drugs. 2017 Jun; 19(3):213-222.
-
Navari RM, Aapro M. Antiemetic Prophylaxis for Chemotherapy-Induced Nausea and Vomiting. N Engl J Med. 2016 Apr 07; 374(14):1356-67.
-
Rapoport B, Schwartzberg L, Chasen M, Powers D, Arora S, Navari R, Schnadig I. Efficacy and safety of rolapitant for prevention of chemotherapy-induced nausea and vomiting over multiple cycles of moderately or highly emetogenic chemotherapy. Eur J Cancer. 2016 Apr; 57:23-30.
-
Navari RM. 5-HT3 receptors as important mediators of nausea and vomiting due to chemotherapy. Biochim Biophys Acta. 2015 Oct; 1848(10 Pt B):2738-46.
-
Navari RM. Palonosetron for the treatment of chemotherapy-induced nausea and vomiting. Expert Opin Pharmacother. 2014 Dec; 15(17):2599-608.
-
Navari RM. Management of chemotherapy-induced nausea and vomiting : focus on newer agents and new uses for older agents. Drugs. 2013 Mar; 73(3):249-62.
-
Navari RM. Palonosetron: a second generation 5-hydroxytryptamine 3 receptor antagonist. Expert Opin Drug Metab Toxicol. 2009 Dec; 5(12):1577-86.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|